BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25246592)

  • 1. Cell fate regulation by gelsolin in human gynecologic cancers.
    Abedini MR; Wang PW; Huang YF; Cao M; Chou CY; Shieh DB; Tsang BK
    Proc Natl Acad Sci U S A; 2014 Oct; 111(40):14442-7. PubMed ID: 25246592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.
    Abedini MR; Muller EJ; Bergeron R; Gray DA; Tsang BK
    Oncogene; 2010 Jan; 29(1):11-25. PubMed ID: 19802016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gelsolin regulates cisplatin sensitivity in human head-and-neck cancer.
    Wang PW; Abedini MR; Yang LX; Ding AA; Figeys D; Chang JY; Tsang BK; Shieh DB
    Int J Cancer; 2014 Dec; 135(12):2760-9. PubMed ID: 24771612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.
    Abedini MR; Muller EJ; Brun J; Bergeron R; Gray DA; Tsang BK
    Cancer Res; 2008 Jun; 68(12):4511-7. PubMed ID: 18559494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.
    Al-Bahlani S; Fraser M; Wong AY; Sayan BS; Bergeron R; Melino G; Tsang BK
    Oncogene; 2011 Oct; 30(41):4219-30. PubMed ID: 21516125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.
    Woo MG; Xue K; Liu J; McBride H; Tsang BK
    J Biol Chem; 2012 Feb; 287(6):3963-75. PubMed ID: 22117079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers.
    Kong B; Wang Q; Fung E; Xue K; Tsang BK
    J Biol Chem; 2014 Sep; 289(39):27134-27145. PubMed ID: 25112877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
    Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
    Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance.
    Asare-Werehene M; Nakka K; Reunov A; Chiu CT; Lee WT; Abedini MR; Wang PW; Shieh DB; Dilworth FJ; Carmona E; Le T; Mes-Masson AM; Burger D; Tsang BK
    Oncogene; 2020 Feb; 39(7):1600-1616. PubMed ID: 31700155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
    Bai L; Wang A; Zhang Y; Xu X; Zhang X
    Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells.
    Le Clorennec C; Lazrek Y; Dubreuil O; Sampaio C; Larbouret C; Lanotte R; Poul MA; Barret JM; Prost JF; Pèlegrin A; Chardès T
    Cell Commun Signal; 2019 Aug; 17(1):106. PubMed ID: 31443721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.
    Kong B; Han CY; Kim SI; Patten DA; Han Y; Carmona E; Shieh DB; Cheung AC; Mes-Masson AM; Harper ME; Song YS; Tsang BK
    J Ovarian Res; 2022 Jun; 15(1):70. PubMed ID: 35668443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
    Sasaki H; Sheng Y; Kotsuji F; Tsang BK
    Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance.
    Manzoor HB; Asare-Werehene M; Pereira SD; Satyamoorthy K; Tsang BK
    J Ovarian Res; 2024 Jan; 17(1):15. PubMed ID: 38216951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal Plasma Gelsolin Is an Immunosuppressive Mediator in the Ovarian Tumor Microenvironment and a Determinant of Chemoresistance.
    Onuma T; Asare-Werehene M; Yoshida Y; Tsang BK
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Gelsolin Inhibits CD8
    Asare-Werehene M; Communal L; Carmona E; Han Y; Song YS; Burger D; Mes-Masson AM; Tsang BK
    Cancer Res; 2020 Sep; 80(18):3959-3971. PubMed ID: 32641415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.